Floxuridine

Floxuridine

Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a682006
Pregnancy category	(US): D
Routes of administration	Intra-arterial
ATC code	none
Identifiers
IUPAC name 5-Fluoro-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione
CAS Number	50-91-9 Y
PubChem (CID)	5790
IUPHAR/BPS	4801
DrugBank	DB00322 Y
ChemSpider	5586 Y
UNII	039LU44I5M Y
KEGG	D04197 Y
ChEBI	CHEBI:60761 Y
ChEMBL	CHEMBL917 Y
ECHA InfoCard	100.000.066
Chemical and physical data
Formula	C9H11FN2O5
Molar mass	246.192 g/mol
3D model (Jmol)	Interactive image
SMILES FC=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)C2)CO
InChI InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1 Y Key:ODKNJVUHOIMIIZ-RRKCRQDMSA-N Y

Floxuridine (also 5-fluorodeoxyuridine) is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colorectal cancer.

Floxuridine, an analog of 5-fluorouracil, is a fluorinated pyrimidine.

Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.

Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to F H Faulding, which became Mayne Pharma.

In the US the drug is supplied by APP Pharmaceuticals, LLC; Hospira, Inc.; and Bedford Laboratories.